NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic …

SHELTON, CT, December 9, 2025 (EZ Newswire) -- NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) today reported that ...

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

Detailed price information for Nanoviricides Inc (NNVC-A) from The Globe and Mail including charting and trades.
Penticton Herald

Rotary Club of LaSalle Centennial Raises Over $6,950 to Help End Polio

The Rotary Club of LaSalle Centennial has announced a major contribution to the global fight against polio, raising $2,318.95 ...